Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
Background: The prognostic factors for efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer remain unknown. The purpose of this study is to evaluate the efficacy of PARP inhibitors and to explore their prognostic factors in ovarian cancer.Methods: PubMed, Embase, and conferenc...
Main Authors: | Xuan-zhang Huang, Han Jia, Qiong Xiao, Run-zhou Li, Xing-shuang Wang, Hai-yan Yin, Xin Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00958/full |
Similar Items
-
The evolving role of PARP inhibitors in advanced ovarian cancer
by: Levva Sofia, et al.
Published: (2021-08-01) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01) -
Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01) -
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
by: Renata Rodrigues da Cunha Colombo Bonadio, et al.
Published: (2018-08-01) -
Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
by: Paul DiSilvestro, et al.
Published: (2021-11-01)